Cargando…

Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients

BACKGROUND: Biomarkers to objectively measure disease severity and predict therapeutic responses are needed in atopic dermatitis (AD). OBJECTIVE: Primary aim: To identify biomarkers reflecting therapeutic response in patients with AD treated systemically. Secondary aims: (i) To identify a biomarker...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roekevisch, E., Szegedi, K., Hack, D.P., Schram, M.E., Res, P.C.J.M., Bos, J.D., Leeflang, M.M.G., Luiten, R.M., Kezic, S., Spuls, P.I., Middelkamp‐Hup, M.A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Allergy and Eczema
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496710/ https://www.ncbi.nlm.nih.gov/pubmed/31855303 http://dx.doi.org/10.1111/jdv.16164

Ejemplares similares

Both children and adult patients with difficult‐to‐treat atopic dermatitis have high prevalences of concomitant allergic contact dermatitis and are frequently polysensitized
por: Boonstra, M., et al.
Publicado: (2018)

The current extent of and need for shared decision making in atopic dermatitis and psoriasis in the Netherlands: an online survey study amongst patients and physicians
por: van der Kraaij, G.E., et al.
Publicado: (2020)

Validation of the Patient‐Oriented SCORing for Atopic Dermatitis tool for black skin
por: Faye, O., et al.
Publicado: (2019)

A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy
por: Paller, A.S., et al.
Publicado: (2020)

Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate‐to‐severe atopic dermatitis from the BREEZE‐AD7 Phase 3 randomized trial
por: Wollenberg, A., et al.
Publicado: (2021)

Can serum biomarkers predict the outcome of systemic immunosuppressive therapy in adult atopic dermatitis patients?
por: Hurault, G., et al.
Publicado: (2022)

Stepwise approach of development of dermo‐cosmetic products in healthy and atopic dermatitis paediatric population: safety evaluation, clinical development and postmarket surveillance
por: Ribet, V., et al.
Publicado: (2019)

Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis
por: Thyssen, J.P., et al.
Publicado: (2021)

Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate‐to‐severe atopic dermatitis: an analysis of patient‐reported outcomes
por: Cork, M.J., et al.
Publicado: (2021)

The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada
por: de Bruin‐Weller, M., et al.
Publicado: (2020)

Defining and measuring ‘eczema control’: an international qualitative study to explore the views of those living with and treating atopic eczema
por: Howells, L., et al.
Publicado: (2019)

A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real‐world study in Belgium
por: Lapeere, H., et al.
Publicado: (2019)

Allergen‐specific immunotherapy with apples: selected cultivars could be a promising tool for birch pollen allergy
por: Nothegger, B., et al.
Publicado: (2020)

Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need
por: Pereira, M.P., et al.
Publicado: (2018)

Relations between a standardized experimental stressor and cutaneous sensory function in patients with chronic pruritus and healthy controls: an experimental case–control study
por: Schneider, G., et al.
Publicado: (2018)

Burden of chronic urticaria relative to psoriasis in five European countries
por: Balp, M.M., et al.
Publicado: (2017)

Emollient efficacy and acceptability in the treatment of eczematous dry skin: A double-blind, randomised comparison of two UK-marketed products
por: Djokic-Gallagher, Jasmina, et al.
Publicado: (2016)

Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series
por: Bosma, A. L., et al.
Publicado: (2021)

Classifying atopic dermatitis: a systematic review of phenotypes and associated characteristics
por: Bosma, A.L., et al.
Publicado: (2022)

Obesity and the microbiome in atopic dermatitis: Therapeutic implications for PPAR-γ agonists
por: McAleer, Jeremy P.
Publicado: (2023)

TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries
por: Vermeulen, F.M., et al.
Publicado: (2019)

Proteomics Profiling to Distinguish DOCK8 Deficiency From Atopic Dermatitis
por: Jacob, Minnie, et al.
Publicado: (2021)

Early inhalant allergen sensitization at component level: an analysis in atopic Dutch children
por: Landzaat, Lonneke J., et al.
Publicado: (2023)

Work ability and quality of working life in atopic dermatitis patients treated with dupilumab
por: Bosma, Angela L., et al.
Publicado: (2021)

TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo‐ and systemic therapy registries
por: Gerbens, L.A.A., et al.
Publicado: (2018)

Asthma improvement in patients treated with dupilumab for severe atopic dermatitis
por: Dubini, Marco, et al.
Publicado: (2023)

Iron-Deficiency in Atopic Diseases: Innate Immune Priming by Allergens and Siderophores
por: Roth-Walter, Franziska
Publicado: (2022)

Survey of topical exposure concerns for patients and caregivers dealing with atopic dermatitis
por: Ratley, Grace, et al.
Publicado: (2023)

Non-atopic Neonatal Thymic Innate Lymphoid Cell Subsets (ILC1, ILC2, and ILC3) Identification and the Modulatory Effect of IgG From Dermatophagoides Pteronyssinus (Derp)-Atopic Individuals
por: de Sousa, Thamires Rodrigues, et al.
Publicado: (2021)

Navigating patients with atopic dermatitis or chronic spontaneous urticaria during the COVID-19 pandemic
por: Haddad, Isabelle, et al.
Publicado: (2022)

Children with atopic eczema experiencing increased disease severity in the pollen season more often have hay fever at a young age and a dark skin type
por: Bosma, Angela Leigh‐Ann, et al.
Publicado: (2021)

Effective Primary Prevention of Atopic Dermatitis in High-Risk Neonates via Moisturizer Application: Protocol for a Randomized, Blinded, Parallel, Three-Group, Phase II Trial (PAF Study)
por: Inuzuka, Yusuke, et al.
Publicado: (2022)

Patients Unmet Needs in Chronic Rhinosinusitis With Nasal Polyps Care: A Patient Advisory Board Statement of EUFOREA
por: Claeys, N., et al.
Publicado: (2021)

Corrigendum: Patients Unmet Needs in Chronic Rhinosinusitis With Nasal Polyps Care: A Patient Advisory Board Statement of EUFOREA
por: Claeys, N., et al.
Publicado: (2021)

Factors predicting the outcome of allergen-specific nasal provocation test in children with grass pollen allergic rhinitis
por: Barreto, M., et al.
Publicado: (2023)

EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care
por: Hellings, P. W., et al.
Publicado: (2023)

β-Glucosylceramide From Allergic Mothers Enhances Offspring Responsiveness to Allergen
por: Walker, Matthew T., et al.
Publicado: (2021)

Peanut butter feeding induces oral tolerance in genetically diverse collaborative cross mice
por: Immormino, Robert M., et al.
Publicado: (2023)

Neutrophil and Eosinophil Responses Remain Abnormal for Several Months in Primary Care Patients With COVID-19 Disease
por: Jukema, B. N., et al.
Publicado: (2022)

TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries
por: Gerbens, Louise A. A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5ernqvaf12f7ikhe851omocl6q